Deferoxamine treatment as a risk factor for zygomycete infection

scientific article published on 01 January 1989

Deferoxamine treatment as a risk factor for zygomycete infection is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1093/INFDIS/159.1.151
P698PubMed publication ID2909637

P2093author name stringS Manzi
J O Moore
J Perfect
A J Herzberg
A Sane
P433issue1
P407language of work or nameEnglishQ1860
P921main subjectdeferoxamineQ419618
P304page(s)151-152
P577publication date1989-01-01
P1433published inJournal of Infectious DiseasesQ4051141
P1476titleDeferoxamine treatment as a risk factor for zygomycete infection
P478volume159

Reverse relations

cites work (P2860)
Q28067212A Review on Iron Chelators in Treatment of Iron Overload Syndromes
Q44357651Effects of deferoxamine, feroxamine and iron on experimental mucormycosis (zygomycosis).
Q33998041Hemoglobin toxicity in experimental bacterial peritonitis is due to production of reactive oxygen species
Q43825222Indolent zygomycosis associated with deferoxamine chelation therapy
Q38704400Mucormycosis: association with deferoxamine therapy
Q42873307Restoration of Hematopoiesis After Iron Chelation Therapy With Deferasirox in 2 Children With Severe Aplastic Anemia
Q37849630The relevance of iron overload and the appropriateness of iron chelation therapy for patients with myelodysplastic syndromes: a dialogue and debate

Search more.